The Russia-Japan Investment Fund invests in Doctis telemedicine platform

Press release, 30.03.2018

Moscow, 30 March 2018 – A consortium of international investors comprising of the Russian Direct Investment Fund (RDIF) and the Russia-Japan Investment Fund (RJIF, launched and advised by RDIF, Japan Bank for International Cooperation and JBIC IG Partners) as well as leading co-investors from the Middle East, has signed a definitive agreement to acquire a minority stake in Doctis, a multifunctional telemedicine service company.

Doctis is developing a universal telemedicine platform using predictive medical technologies and artificial intelligence. This platform aims to make high-quality medical care easily available to the Russian population. Doctis expects that users of their platform could exceed 10 million people in the long-run, and its business could introduce substantial number of Japanese medical and healthcare devices in the Russian market. The company aspires to be the industry leader in the rapidly developing Russian telemedicine market.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:
"The investment in Doctis is another step in growing RDIF's portfolio of tech projects which we announced previously. Doctis’ platform will combine leading medical expertise with pioneering information and communication technologies. Alongside our partners, we are pleased to support the development of the promising project that will improve the quality of life and the efficiency of medical care for people across Russia, particularly those in remote regions."

Igor Vornovitsky, Doctis CEO, said:
“Doctis is now fully focused on integrating as many services as possible into the platform. We have already implemented online consultations and appointments; we provide technologies for remote monitoring and support during pregnancy and we are integrating the platform with a wide range of medical equipment. Hundreds of users are asking questions to doctors every day with the help of the Doctis service. According to our estimates, very soon we will reach the level of more than two million consultations annually.
We plan to use artificial intelligence to diagnose, identify the symptoms of diseases and their pathologies as well as in many other areas. We see that cooperation with the Russian Direct Investment Fund and the Russian-Japanese Investment Fund will help us become one of the most advanced telemedicine services – a one-stop shop where one can get swift and detailed answers to any health issues.”


Russia-Japan Investment Fund was established to pursue and implement attractive investment projects, which promote economic trade and investment cooperation between Japan and Russia. Priority sectors identified for cooperation include healthcare, energy, developing industries, smart cities, cutting-edge and sustainable technologies, and Russian Far Eastern District exports. It also works to support initiatives that will strengthen trade and economic relations between the two countries.

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Further information can be found at

Doctis is a multifunctional healthcare online platform. It operates an online medical centre that allows patients to comprehensively evaluate and track their health. It partners with the state and private clinics and experts to provide services based on user's personal medical data, utilising a single online medical data storage system, which includes medical records of all family members.

For additional information contact:
Arseniy Palagin
Russian Direct Investment Fund
Press Secretary
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41

Andrew Hayes / Elena Garside
Hudson Sandler
Tel: +44 (0) 20 7796 4133

Irina Andrievskaya
Press Secretary
Tel: +7 499 490-17-13
Mobile: +7 926 350-35-59